TITLE

Approving pre-surgery cancer drugs

PUB. DATE
November 2013
SOURCE
Nature Reviews Drug Discovery;Nov2013, Vol. 12 Issue 11, p817
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has approved the pertuzumab, a neoadjuvant breast cancer drug, from medical companies Roche and Genentech.
ACCESSION #
91716377

 

Related Articles

  • New Treatment for Advanced Breast Cancer.  // Clarendon Enterprise (TX);11/1/2007, Vol. 18 Issue 46, p7 

    The article reports that the Food and Drug Administration (FDA) has approved the Ixempera, a new treatment for advanced breast cancer in the U.S.

  • Targeted therapies continue to improve outcomes in HER-2--positive breast cancer. Southall, Jennifer R. // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p1 

    The article focuses on the move of the U.S. Food and Drug Administration (FDA) to approve ado-trastuzumab emtansine for HER-2-positive breast cancer treatment, which will fourth drug approved by the regulatory board for use against the said disease.

  • LEGAL/REGULATORY.  // Medical Marketing & Media;Feb2016, Vol. 51 Issue 2, p9 

    The article focuses on several drugs approved by the U.S. Food & Drug Administration (FDA) in 2015 including the Pfizer's Ibrance, breast-cancer treatment, Boehringer Ingelheim's Praxbind, drug that changes the blood-thinning effects of the anticoagulants, and the Okambi, cystic fibrosis treatment.

  • Ixabepilone Treatment Schedules in Advanced Breast Cancer. Egerton, Nancy // European Journal of Clinical & Medical Oncology;2012, Vol. 4 Issue 1, p49 

    Ixabepilone, the first of a new class of microtubule-stabilizing anticancer agents, is approved in 17 countries worldwide. It was approved by the Food and Drug Administration in 2007 for treatment of patients with locally advanced or metastatic breast cancer progressing after taxanes and...

  • Genentech Caught off Guard, FDA Issues Refuse-to-File for T-DM1. Hollingsworth, Catherine // BioWorld Today;8/30/2010, Vol. 21 Issue 167, p1 

    The article focuses on a refuse-to-file letter sent by the U.S. Food and Drug Administration (FDA) to Genentech Inc. rejecting its application for an accelerated approval of its trastuzumab-DNA methyltransferase inhibitor (T-DMI). Genentech conducted a study which indicated that T-DMI reduced...

  • Breast-Case Scenario: Kadcyla Price Set at Premium to Others. Osborne, Randy // BioWorld Today;2/25/2013, Vol. 24 Issue 36, p1 

    The article reports on the controversial approval of the antibody drug Kadcyla by the Food and Drug Administration (FDA). The antibody drug conjugate (ADC) is a high-cost combination therapy for Herceptin (trastuzumab) with ImmunoGen Inc.'s DM1 maytansinoid cell-killing agent to treat...

  • Pfizer seeks cancer drug nod. Investor's Business Daily // Investors Business Daily;5/19/2014, pA02 

    Top U.S. drugmaker by market value

  • FDA Approves A New Type Of Breast Cancer Drug.  // RN;Mar2005, Vol. 68 Issue 3, p80 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new type of breast cancer drug. The first drug in a new class of medications known as proteinbound particle drugs has been approved for treating metastatic breast cancer in patients for whom combination...

  • GlaxoSmithKline: Tykerb filed for approval.  // PharmaWatch: Monthly Review;Nov2006, Vol. 5 Issue 11, p7 

    The article reports that GlaxoSmithKline PLC has submitted Tykerb, an experimental drug to be used in the treatment of metastatic breast cancer, for regulatory approval by the U.S. Food & Drug Administration. It has been found that Tykerb is able to double the time to disease progression in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics